Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml oral solution
The product will be manufactured at the plant of Bell, Sons & Co, UK
Marksans Pharma | 24/01/2023 | By Sudeep Soparkar
Marksans acquires capacity from Tevapharm India, plans to double its manufacturing footprint
The transaction is in cash consideration and is expected to be finalised by April 1, 2023, subject to the usual closing conditions
Marksans Pharma | 12/10/2022 | By Sudeep Soparkar
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.